Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

QURE

Phase 1/2

AMT-260

(MTLE) Refractory mesial temporal lobe epilepsy

2025

GenTLE trial. 9/5/23- IND cleared. 8/1/24- Trial initiated. 11/21/24- First patient dosed. Provide program updates in 2025.

Data readout

VSTM

Phase 2

Avutometinib (VS-6766) + LUMAKRAS (sotorasib)

NSCLC (KRAS G12C mutant)

H2 2025

RAMP 203 study. Collab agreement w/ Amgen. Enrollment ongoing in the expansion phase. 11/6/24- Report updated interim data by the end of 2024. 12/18/24- No dose-limiting toxicity observed. Additional enrollment expected, interim update in H2 2025.

Data readout

SANA

Phase 1

SC291 (CD19)

Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

2025

GLEAM trial. 11/9/23- IND cleared. 12/2/24- Granted fast track designation. Report initial clinical data in 2025.

Data readout

PEPG

Phase 1

PGN-EDODM1

Myotonic dystrophy type 1 (DM1)

H2 2025

FREEDOM-DM1 study. 10/12/23- Lifted clinical hold. 12/18/23- First patient dosed. 2/24/25- Reported initial results. Dosing 15 mg/kg cohort, with results in H2 2025.

Data readout

PRAX

Phase 2/3

PRAX-628

Focal onset seizures (FOS) or epilepsy

H2 2025

POWER1 & POWER2: 8/13/24 Enrolling start (POWER1) in Q4 2024 & topline results in H2 2025. POWER2 start enrolling patients in H1 2025.

Data readout

GNFT

Phase 2

VS-01

Acute on-chronic liver failure (ACLF)

2025

UNVEIL-IT: 9/19/24 new protocol & Interim data readout in 2025.

Data readout

APGE

Phase 1

APG990

Atopic dermatitis

2025

Ph1 initiation in H2 2024. 8/19/24- Ph 1 initiated with first patient dosed. Interim safety and PK data in 2025.

Data readout

IBRX

Phase 1

CAR-NK / CD19 t-haNK

Non-Hodgkin’s lymphoma (NHL)

H2 2025

10/24/24 First patient dosed in Africa. Complete enrollment in Q1 '25 & topline data readout in H2 '25

Data readout

SANA

Phase 1

UP421

Type 1 diabetes

2024 and/or 2025

11/4/24- Share proof of concept data in 2024 and/or 2025.

Data readout

FDMT

Phase 2b

4D-150

Wet AMD

Q4 2025

PRISM (Ph2b) & 4FRONT-1 (Ph3) trials. 2/8/25- Presented initial interim 52-wk results at AED '25. 2-year Ph1/2a & 18-month Ph2b PRISM data in Q4 2025. 3/10/25- First patients enrolled in 4FRONT-1 Ph3 trial. Initiate 4FRONT-2 in Q3 2025. Topline primary endpoint data from both trials in H2 2027.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20